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The interaction between the SARS-CoV-2 virus Spike protein receptor binding domain (RBD) 3 
and the ACE2 cell surface protein is required for viral infection of cells. Mutations in the RBD 4 
domain are present in SARS-CoV-2 variants of concern that have emerged independently 5 
worldwide. For example, the more transmissible B.1.1.7 lineage has a mutation (N501Y) in 6 
its Spike RBD domain that enhances binding to ACE2. There are also ACE2 alleles in humans 7 
with mutations in the RBD binding site. Here we perform a detailed affinity and kinetics 8 
analysis of the effect of five common RBD mutations (K417N, K417T, N501Y, E484K and 9 
S477N) and two common ACE2 mutations (S19P and K26R) on the RBD/ACE2 interaction.  10 
We analysed the effects of individual RBD mutations, and combinations found in new SARS-11 
CoV-2 variants first identified in the UK (B.1.1.7), South Africa (B.1.351) and Brazil (P1). Most 12 
of these mutations increased the affinity of the RBD/ACE2 interaction. The exceptions were 13 
mutations K417N/T, which decreased the affinity.  Taken together with other studies, our 14 
results suggest that the N501Y and S477N mutations primarily enhance transmission, the 15 
K417N/T mutations facilitate immune escape, and the E484K mutation facilitates both 16 
transmission and immune escape. 17 
 18 
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 3 
Introduction 19 
Since its identification in 2019, the second coronavirus able to induce a severe acute 20 
respiratory syndrome in humans, SARS-CoV-2, has resulted in the most severe global 21 
pandemic in 100 years. To date more than 135 million people have been infected, resulting 22 
in the deaths from the resulting disease, COVID-19, of more than 3 million people (“WHO 23 
Coronavirus (COVID-19) Dashboard,” 2021), and measures introduced to control spread 24 
have had harmful social and economic impacts. Fortunately, effective vaccines have been 25 
developed, and a global vaccination programme is underway (Mahase, 2021). New SARS-26 
CoV-2 variants of concern are emerging that are making containment of the pandemic more 27 
difficult, by increasing transmissivity of the virus (Davies and Edmunds, 2021; Korber et al., 28 
2020; Volz et al., 2021a, 2021b; Washington et al., 2021) and/or its resistance to protective 29 
immunity induced by previous infection or vaccines (Darby and Hiscox, 2021; Dejnirattisai et 30 
al., 2021; Garcia-Beltran et al., 2021; Madhi et al., 2021a, 2021b; Mahase, 2021).(Volz et al., 31 
2021a, 2021b) 32 
The SARS-CoV-2 virus enters cells following an interaction between the Spike (S) protein on 33 
its surface with angiotensin-converting enzyme 2 (ACE2) on cell surfaces (V’kovski et al., 34 
2021). The receptor binding domain (RBD) of the Spike protein binds the membrane-distal 35 
portion of the ACE2 protein. The S protein forms a homotrimer, which is cleaved shortly 36 
after synthesis into two fragments that remain associated non-covalently:  S1, which 37 
contains the RBD, and S2, which mediates membrane fusion following the binding of Spike 38 
to ACE2 (V’kovski et al., 2021). During the pandemic mutations have appeared in the Spike 39 
protein that apparently increase transmissivity (Davies and Edmunds, 2021; Korber et al., 40 
2020; Volz et al., 2021a, 2021b; Washington et al., 2021). One that emerged early in Europe, 41 
D614G, and quickly became dominant globally (Korber et al., 2020), increases the density of 42 
intact Spike trimer on the virus surface by preventing premature dissociation of S1 from S2 43 
following cleavage (Zhang et al., 2021, 2020). A later mutant, N501Y, which has appeared in 44 
multiple lineages, lies within the RBD domain, and increases its affinity for ACE2 (Starr et al., 45 
2020; Supasa et al., 2021). These findings suggest that mutations that directly or indirectly 46 
enhance Spike binding to ACE2 will increase transmissivity.  47 
Prior infection by SARS-CoV-2 and current vaccines induce antibody responses to the Spike 48 
protein, and most neutralizing antibodies appear to bind to the Spike RBD domain (Garcia-49 
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 4 
Beltran et al., 2021; Greaney et al., 2021a; Rogers et al., 2020). Some variants of concern 50 
have mutations in their RBD domain that confer resistance to neutralizing antibodies (Darby 51 
and Hiscox, 2021; Dejnirattisai et al., 2021; Garcia-Beltran et al., 2021; Madhi et al., 2021a, 52 
2021b; Mahase, 2021). What is less clear is the precise effect of these mutations on the 53 
affinity and kinetics of the binding of RBD to ACE2. Previous studies of the interaction 54 
between the Spike RBD and ACE2 have produced a wide range of affinity and kinetic 55 
estimates under conditions (e.g. temperature) that are not always well defined (Lei et al., 56 
2020; Shang et al., 2020; Supasa et al., 2021; Wrapp et al., 2020; Zhang et al., 2021, 2020). 57 
Precise information is needed to assess the extent to which RBD mutations have been 58 
selected because they enhance ACE2 binding or facilitate immune evasion. 59 
In this study we undertook a detailed affinity and kinetic analysis of the interaction between 60 
Spike RBD and ACE2 at physiological temperatures, taking care to avoid common pitfalls. 61 
We used this optimized approach to analyse the effect of important common mutations 62 
identified in variants of RBD and ACE2. Both mutations of ACE2 (S19P, K26R) and most of 63 
the mutations of RBD (N501Y, E484K, and S477N) enhanced the interaction, with some RBD 64 
mutations (N501Y) increasing the affinity by ~10 fold. Increased binding was the result of 65 
decreases in dissociation rate constants (N501Y, S477N) and/or increases in association rate 66 
constants (N501Y, E484K). Although the K417N/T mutations found in the South African 67 
(B.1.351) and Brazilian (P.1) variants both decreased the affinity, the affinity-enhancing 68 
N501Y and E484K mutations that are also present in both variants confer a net ~4 fold 69 
increase in the affinity of their RBD domains for ACE2. 70 
Results 71 
Selection of variants 72 
The focus of this study was to analyse common and therefore important variants of RBD and 73 
ACE2.  Henceforth we will refer to the common ACE2 allele and RBD of the original SARS-74 
CoV-2 strain sequenced in Wuhan as wild-type (WT). We chose mutations of RBD within the 75 
ACE2 binding site that have appeared independently in multiple SARS-CoV-2 lineages/clades 76 
(Fig. 1 and Fig. S1) (Hodcroft, 2021; Rambaut et al., 2020), suggesting that they confer a 77 
selective advantage, rather than emerged by chance, such as through a founder effect. The 78 
N501Y mutation has appeared in the B.1.1.7 (20I/501Y.V1), B.1.351 (20H/501Y.V2), and P.1 79 
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 5 
lineages (20J/501Y.V3) first identified in the UK, South Africa and Brazil, respectively. The 80 
E484K mutation is present in the B.1.351 and P.1 lineages and has appeared independently 81 
in many other lineages, including P.2 (20B/S.484K), B.1.1.318, B.1.525 (20A/S:4.4K), and 82 
B.1.526 (20C/S.484K). E484K has also appeared in VOC-202102-02, a subset of the B.1.1.7 83 
lineage identified in the UK (“SARS-CoV-2 Variants of concern and variants under 84 
investigation - GOV.UK,” 2021) . The S477N mutation became dominant for periods in 85 
Australia (clade 20F) and parts of Europe (20A.EU2), and then appeared in New York in 86 
lineage B.1.526 (H. Zhou et al., 2021). Mutations of K417 have appeared independently in 87 
the South African B.1.351 and Brazilian P.1 lineages. Interestingly, N501Y, E484K and S477N 88 
were the main mutations that appeared following random RBD mutagenesis and in vitro 89 
selection of mutants with enhanced ACE2 binding (Zahradník et al., 2021). 90 
We selected for analysis the two most common mutations of ACE2 within the RBD binding 91 
site, K26R and S19P (Fig. 1C). They are present in 0.4% and 0.03%, respectively, of all 92 
samples in the gnomAD database (Karczewski et al., 2020), while other ACE2 mutations in 93 
the RBD binding site are much less frequent (<0.004%) (MacGowan et al., 2021). K26R is 94 
observed in all the major gnomAD populations but is most common in Ashkenazi Jews (1%), 95 
and (non-Finnish) north-western Europeans (0.6%). It is less common in Africans/African-96 
Americans and South Asians (0.1%) and rare in Finnish (0.05%) and East-Asian (0.001%) 97 
populations. The S19P mutant is almost exclusively found in Africans/African-Americans (0.3 98 
%).  99 
Measurement of affinity and kinetics 100 
To measure the effects of these mutations on the affinity and kinetics of the RBD/ACE2 101 
interaction we used surface plasmon resonance, which allows very accurate measurements, 102 
provided that common pitfalls are avoided, particularly protein aggregation, mass-transport 103 
limitations and rebinding (van der Merwe and Barclay, 1996; Myszka, 1997). Monomeric, 104 
soluble forms of the ectodomain of the ACE2 and the Spike RBD-domain were expressed in 105 
human cells, to retain native glycosylation, and purified (Fig. S2). ACE2 was captured onto 106 
the sensor surface via a carboxy-terminal biotin and RBD injected over the ACE2 at different 107 
concentrations (Fig. 2A). Excellent fits of 1:1 Langmuir binding model to the data yielded an 108 
association rate constant (kon) of 0.9 ± 0.05 M-1.s-1 and a dissociation rate constant (koff) of 109 
0.067 ± 0.0011 s-1 (mean ± SD, n=6, Table 1).  These rate constants are 3 to 25 fold faster 110 
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 6 
than previously reported for the same interaction (Lei et al., 2020; Shang et al., 2020; 111 
Supasa et al., 2021; Wrapp et al., 2020; Zhang et al., 2021). However, previous experiments 112 
were conducted at unphysiologically low temperatures (i.e. below 37° C) and under 113 
conditions in which mass-transport limitations and rebinding are highly likely (see 114 
Discussion). These factors, and the presence of protein aggregates, would all lower the 115 
measured rate constants. In contrast, our measurements were conducted at 37° C and 116 
under conditions in which mass-transfer limitation and rebinding were excluded. The latter 117 
is demonstrated by the fact that measured kon and koff rates were clearly maximal at the low 118 
level of ACE2 immobilization (~50 RU) used in our experiments (Fig. 2B and C). The excellent 119 
fit of the 1:1 binding model to our data excludes an effect of protein aggregates, which yield 120 
complex kinetics. The calculated dissociation constant (KD) was 74 ± 4 nM (mean ± SD, n=6, 121 
Table 1). We also measured KD by equilibrium binding (Fig. 2D), which avoids any artefacts 122 
induced by mass transfer limitations and rebinding. This KD determined by equilibrium 123 
binding was very similar to the value calculated from kinetic data [63 ± 7.7 nM (mean ± SD, 124 
n = 24, Table 1], and did not vary with immobilization level (Fig. 2E), further validating our 125 
kinetic measurements. These affinity values are within the wide range reported in previous 126 
studies, which varied from KD 11 to 133 nM (Lei et al., 2020; Shang et al., 2020; Supasa et al., 127 
2021; Wrapp et al., 2020; Zhang et al., 2021). 128 
The effect of RBD mutations  129 
We next evaluated the effect of RBD mutations on the affinity and kinetics of binding to 130 
ACE2 (Figure 3 and Table 1). Example sensorgrams are shown of mutations that increased 131 
(N501Y, Fig. 3A) or decreased (K417N, Fig. 3B) the binding affinity, while the key results 132 
from all mutants are summarized in Figure 3C. The single mutations S477N, E484K and 133 
N501Y all enhanced binding. The N501Y mutation had the biggest effect, increasing the 134 
affinity ~10 fold to KD ~7 nM, by increasing the kon ~1.8 fold and decreasing the koff by ~ 7-135 
fold.  The S477N and E484K mutations increased the affinity more modestly (~ 1.5-fold), by 136 
decreasing the koff (S477N) or increasing the kon (E484K). The K417T and K417N mutations 137 
decreased the affinity ~2 and ~4 fold, respectively, mainly by decreasing the kon but also by 138 
increasing the koff. Affinity-altering mutations in binding sites mainly affect the koff (Agius et 139 
al., 2013) and have more modest effects on the kon. Changes in electrostatic interactions can 140 
dramatically affect the kon (Schreiber and Fersht, 1996), and are a plausible explanation for 141 
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 7 
the effects of the mutations K417T, K417N and E484K on kon. K417 forms a salt bridge with 142 
D30 on ACE2 (Lan et al., 2020) while E484 is ~9 Å from E75 on ACE2 (Lan et al., 2020). Thus 143 
the mutations K417N/T and E484K would decrease and increase, respectively, long-range 144 
electrostatic forces that may accelerate association (Schreiber and Fersht, 1996). 145 
We also examined the effect on ACE2 binding of combinations of RBD mutations, including 146 
combinations present in VOC-202102-02, a subset of the B.1.1.7 lineage (N501Y) with the 147 
E484K mutation(“SARS-CoV-2 Variants of concern and variants under investigation - 148 
GOV.UK,” 2021), and the B.1.351 and P.1 variants (Fig. 3C, Table 1). In the case of VOC-149 
202102-02, the addition of the E484K mutation to N501Y further increased the affinity, to 150 
~15 fold higher than WT RBD (KD ~5 nM), by further increasing the kon. Because the higher 151 
kon could result in mass transfer limiting binding, we confirmed that the kinetic 152 
measurement for this variant was not substantially affected by varying levels of 153 
immobilization (Fig. S4). The affinity of the B.1.351 (K417N/ E484K/N501Y) and P.1 154 
(K417T/E484K/N501Y) RBD variants for ACE2 increased by 3.7 and 5.3 fold, respectively, 155 
relative to wild type RBD, by both increasing the kon and decreasing the koff rate constants.  156 
We next examined whether the effects of the mutations were additive, as is typically the 157 
case for multiple mutations at protein/protein interfaces (Wells, 1990). To do this we 158 
converted the changes in KD to changes in binding energy (G, Table 2) and examined 159 
whether the G measured for RBD variants with multiple mutations was equal to the sum 160 
of the G values measured for the individual RBD mutants. This was indeed the case (Fig. 161 
3D), indicating that the effects on each mutation are independent. This is consistent with 162 
them being spaced well apart within the interface (Fig. 1C), and validates the accuracy of 163 
the affinity measurements. 164 
The effects of ACE2 mutations  165 
We next examined the effects of mutations of ACE2 (S19P and K26R) on binding to both wild 166 
type and common variants of RBD (Fig. 4 and Table 1). Both S19P and K26R increased the 167 
affinity of WT RBD binding by ~3.7 and ~2.4 fold (Fig. 4A). These increases in affinity were 168 
the result of both increases in the kon and decreases in the koff. 169 
Finally, we looked for interactions between RBD and ACE2 mutations by measuring the 170 
effects of the ACE2 mutations on binding to all mutant forms of RBD (Table 1).  After 171 
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 8 
converting changes in KD to G (Table 2) we examined whether G measured for a given 172 
ACE2 variant/RBD variant interaction was equal to the sum of the G measured for ACE2 173 
variant/RBD WT and ACE WT/RBD variant interactions. This is depicted as the difference 174 
between the measured and predicted G for interactions between ACE2 and RBD variants 175 
(G in Figs. 4B and C). In most cases G values were close to zero, indicating that the 176 
effects of these mutations were largely independent. The one exception was the 177 
combination of ACE2 S19P and RBD S477N variants, where the measured value was 178 
significantly lower than the predicted value (Fig. 4B), indicating that these mutations were 179 
not independent. This is consistent with the fact that the ACE2 residue S19 is adjacent to 180 
RBD residue S477 in the contact interface (Fig. 1C). An important consequence of this is that 181 
the S477N mutation increased the affinity of RBD for ACE2 WT but decreased its affinity for 182 
ACE2 S19P.  183 
Discussion 184 
While our finding that the SARS-CoV-2 RBD binds ACE2 with an affinity of KD 74 nM at 37°C 185 
is consistent with previous studies (KD 11 to 133 nM) (Lei et al., 2020; Shang et al., 2020; 186 
Supasa et al., 2021; Wrapp et al., 2020; Zhang et al., 2021, 2020), the rate constants that we 187 
measured (kon 0.9 M-1.s-1 and koff 0.067 s-1) were more than 3 fold faster than all previous 188 
reports. One likely reason for this is that previous measurements were performed at a lower 189 
temperature, which almost always decreases rate constants. While one study stated that 190 
binding constants were measured at 25°C (Zhang et al., 2020), most studies did not report 191 
the temperature, suggesting that they were performed at room temperature or the 192 
standard instrument temperature (20-25°C).  A second likely reason is that previous kinetic 193 
studies were performed under conditions in which the rate of diffusion of soluble molecule 194 
to the sensor surface limits the association rate, and rebinding of dissociated molecules to 195 
the surface reduces the measured dissociation rate. These are known pitfalls of both 196 
techniques used in these studies, surface plasmon resonance (Myszka, 1997) and bilayer 197 
interferometry (Abdiche et al., 2008). In the present study we avoided these issues by 198 
immobilizing a very low level of ligand on the sensor surface. A third possible reason is that 199 
the proteins were aggregated, which can cause problems even when aggregates are a very 200 
minor contaminant (van der Merwe and Barclay, 1996). The presence of aggregates results 201 
in complex binding kinetics, which can be excluded if the simple 1:1 Langmuir binding model 202 
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 9 
fits the kinetic data. While this was demonstrated in the present study, and some previous 203 
studies (Shang et al., 2020; Wrapp et al., 2020; Zhang et al., 2021), such fits were not shown 204 
in all studies, one of which reported more than 20 fold slower kinetics than reported here 205 
(Lei et al., 2020; Supasa et al., 2021).  206 
The RBD mutants that we selected for analysis have all emerged independently and become 207 
dominant in a region at least once in different lineages, suggesting that they provide a 208 
selective advantage. Our finding that the N501Y, E484K, and S477N all increase the binding 209 
affinity of RBD for ACE2 raises the question as to whether this contributed to their selection. 210 
Several lines of evidence suggest that enhancing the Spike/ACE2 interaction would be 211 
advantageous.  Firstly, the virus has spread only very recently to humans from another 212 
mammalian host, providing insufficient time for optimization of the affinity. Secondly, 213 
epidemiological studies have demonstrated enhanced transmissibility of the B.1.1.7 variant, 214 
which has the N501Y mutation (Volz et al., 2021b; Washington et al., 2021). Finally, a SARS-215 
CoV-2 variant with the Spike mutation D614G, which increases its activity by stabilizing it 216 
following furin cleavage (Zhang et al., 2021, 2020), rapidly became dominant globally after it 217 
emerged (Korber et al., 2020; Volz et al., 2021a). Taken together, these findings suggest that 218 
the WT Spike/ACE2 interaction is limiting for transmission, and that mutations which 219 
enhance it, including the N501Y, E484K, and S477N mutations, would provide a selective 220 
advantage by increasing transmissibility.  This raises two questions. Firstly, will other RBD 221 
mutations appear in SARS-CoV-2 which further enhance transmission? This seems likely, 222 
given that a large number of RBD mutations have been identified that increase the 223 
RBD/ACE2 affinity (Starr et al., 2020; Zahradník et al., 2021).  Secondly, will combinations of 224 
existing mutations be selected because they further increasing the affinity? While the 225 
appearance E484K together with the N501Y in three lineages (B.1.1.7, B.1.351 and P.1) 226 
supports this, it is also possible that E484K was selected because it disrupts antibody 227 
neutralization, as discussed below. 228 
Studies of other enveloped viruses, including SARS-CoV-2, suggest that increases in affinity 229 
of viral fusion ligands for their cellular receptors can increase cell infection and disease 230 
severity (Hasegawa et al., 2007; Li et al., 2005). One study found that increasing this affinity 231 
enabled the virus to infect cells with lower receptor surface density (Hasegawa et al., 2007).  232 
It follows that increases in affinity could increase the number of host tissues infected, which 233 
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could increase the severity of disease (Cao and Li, 2020) and/or increase the viral load in the 234 
upper respiratory tract el (Hoffmann et al., 2020; Wölfel et al., 2020), thereby increasing 235 
spread.  236 
Another mechanism by which mutations of RBD could provide a selective advantage is 237 
through evasion of immune responses. This is supported by the observation that 238 
neutralizing antibodies present in those infected by or vaccinated against SARS-CoV-2 239 
primarily target the RBD domain (Garcia-Beltran et al., 2021; Greaney et al., 2021a; Rogers 240 
et al., 2020). Furthermore, two variants with RBD mutations that abrogate antibody 241 
neutralization, B.1.351 and P1, became dominant in regions with very high levels of prior 242 
SARS-CoV-2 infection (Cele et al., 2021; Dejnirattisai et al., 2021; Hoffmann et al., 2021; 243 
Sabino et al., 2021; Tegally et al., 2021; D. Zhou et al., 2021). Both lineages include the 244 
N501Y mutation, but this appears to have modest effects on antibody neutralization 245 
(Greaney et al., 2021a, 2021b). In contrast, the E484K mutation, also present in both 246 
lineages, potently disrupts antibody neutralization (Greaney et al., 2021a, 2021b). Our 247 
finding that the K417N/T mutants present in B.1.351/P.1 lineages decrease the affinity of 248 
RBD for ACE2 suggests that they were selected because they facilitate immune escape. 249 
Indeed, mutations of K417 can block antibody neutralization, albeit less effectively than 250 
E484K (Greaney et al., 2021a, 2021b; Wang et al., 2021).  It is notable that these affinity-251 
reducing K417N/T mutants have only emerged together with mutants (N501Y and E484K) 252 
that increase the affinity of RBD for ACE2, suggesting a cooperative effect between 253 
mutations that enhance immune escape and mutations that increase affinity. 254 
The effect of the increased affinity for SARS-CoV-2 Spike RBD of the K26R and S19P ACE2 255 
mutants are less clear. The evidence summarised above that WT RBD/ACE2 binding is 256 
limiting for SARS-CoV-2 transmission, suggest that carriers of these ACE2 variants will be at 257 
greater risk of infection and/or severe disease.  However, in contrast to SARS-CoV-2 RBD 258 
mutations, the effects of ACE2 variants are primarily relevant to the carriers of these 259 
mutations. A preliminary analysis (MacGowan et al., 2021) suggests that the carriers of the 260 
K26R ACE allele might be at increased risk of severe disease, but the findings did not reach 261 
statistical significance, and further studies are required. 262 
The interaction that we identified between the RBD S477N and ACE2 S19P mutants 263 
highlights the importance of considering variation in the host population when studying the 264 
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evolution of viral variants. In this case, the opposite effect of the RBD S477N mutation on its 265 
affinity for ACE2 S19P (decreased) compared with ACE2 WT (increased), suggests that this 266 
RBD variant may have a selective disadvantage amongst carriers of the ACE2 S19P variant, in 267 
contrast to those with ACE2 WT, where it appears to be advantageous.  However, the low 268 
frequency of this variant means that this is unlikely to be important at a population level 269 
and will be difficult to detect. 270 
It is noteworthy that the two most common ACE2 variants are in positions on ACE2 with no 271 
known functional activity. This raises the question as to whether these mutations are a 272 
remnant of historic adaption to pathogens that utilised this portion of ACE2. The fact that 273 
ACE2 S19P mutation is largely confined to African/African-American populations, suggests 274 
that it is more recent than K26R and/or selected by pathogen(s) confined to the African 275 
continent. 276 
Materials and Methods  277 
ACE2 and RBD variant constructs 278 
The soluble WT ACE2 construct, which was kindly provided by Ray Owens (Oxford Protein 279 











The carboxy-terminal end has a biotin acceptor peptide (underlined) followed by an 291 
oligohistidine tag. 292 
The WT RBD construct, which was kindly provided by Quentin Sattentau (Sir William Dunn 293 
School of Pathology), encoded the following protein: 294 
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The carboxy-terminal end has an oligohistidine tag. 299 
ACE2 and RBD point mutations were introduced using the Agilent QuikChange II XL Site-300 
Directed Mutagenesis Kit following the manufacturer’s instructions. The primers were 301 
designed using the Agilent QuikChange primer design web program. 302 
HEK293F cell transfection 303 
Cells were grown in FreeStyle™ 293 Expression Medium (12338018) in a 37 °C incubator 304 
with 8% CO2 on a shaking platform at 130 rpm. Cells were passaged every 2-3 days with the 305 
suspension volume always kept below 33.3% of the total flask capacity. The cell density was 306 
kept between 0.5 and 2 million per ml. Before transfection cells were counted to check cell 307 
viability was above 95% and the density adjusted to 1.0 million per ml. For 100 ml 308 
transfection, 100 µl FreeStyle™ MAX Reagent (16447100) was mixed with 2 ml Opti-MEM 309 
(51985034) for 5 minutes. During this incubation 100 µg of expression plasmid was mixed 310 
with 2 ml Opti-MEM. For in situ biotinylation of ACE2 90 µg of expression plasmid was 311 
mixed with 10 µg of expression plasmid encoding the BirA enzyme. The DNA was then 312 
mixed with the MAX Reagent and incubated for 25 minutes before being added to the cell 313 
culture. For ACE2 in situ biotinylation, biotin was added to the cell culture at a final 314 
concentration of 50 µM. The culture was left for 5 days for protein expression to take place.   315 
Protein purification 316 
Cells were harvested by centrifugation and the supernatant collected and filtered through a 317 
0.22 μm filter. Imidazole was added to a final concentration of 10 mM and PMSF added to a 318 
final concentration of 1 mM. 1 ml of Ni-NTA Agarose (30310) was added per 100 ml of 319 
supernatant and the mix was left on a rolling platform at 4 °C overnight. The supernatant 320 
mix was poured through a gravity flow column to collect the Ni-NTA Agarose. The Ni-NTA 321 
Agarose was washed 3 times with 25 ml of wash buffer (50 mM NaH2PO4, 300 mM NaCl and 322 
20 mM imidazole at pH 8). The protein was eluted from the Ni-NTA Agarose with elution 323 
buffer (50 mM NaH2PO4, 300 mM NaCl and 250 mM imidazole at pH 8). The protein was 324 
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concentrated, and buffer exchanged into size exclusion buffer (25 mM NaH2PO4, 150 mM 325 
NaCl at pH 7.5) using a protein concentrator with a 10,000 molecular weight cut-off. The 326 
protein was concentrated down to less than 500 μl before loading onto a Superdex 200 327 
10/300 GL size exclusion column (Fig. S2). Fractions corresponding to the desired peak were 328 
pooled and frozen at -80 °C. Samples from all observed peaks were analysed on an SDS-329 
PAGE gel (Fig. S2). 330 
Surface plasmon resonance (SPR) 331 
RBD binding to ACE2 was analysed on a Biacore T200 instrument (GE Healthcare Life 332 
Sciences) at 37°C and a flow rate of 30 µl/min. Running buffer was HBS-EP (BR100669). 333 
Streptavidin was coupled to a CM5 sensor chip (29149603) using an amine coupling kit 334 
(BR100050) to near saturation, typically 10000-12000 response units (RU). Biotinylated 335 
ACE2 WT and variants were injected into the experimental flow cells (FC2–FC4) for different 336 
lengths of time to produce desired immobilisation levels (40–800 RU). FC1 was used as a 337 
reference and contained streptavidin only. Excess streptavidin was blocked with two 40 s 338 
injections of 250 µM biotin (Avidity). Before RBD injections, the chip surface was 339 
conditioned with 8 injections of the running buffer. A dilution series of RBD was then 340 
injected in all FCs. Buffer alone was injected after every 2 or 3 RBD injections. The length of 341 
all injections was 30 s, and dissociation was monitored from 180-670 s. The background 342 
response measured in FC1 was subtracted from the response in the other three FCs. In 343 
addition, the responses measured during buffer injections closest in time were subtracted. 344 
Such double-referencing improves data quality when binding responses are low as needed 345 
to obtain accurate kinetic data (Myszka, 1999). At the end of each experiment an ACE2-346 
specific mouse monoclonal antibody (NOVUS Biologicals, AC384) was injected at 5 µg/ml for 347 
10 minutes to confirm the presence and amount of immobilized ACE2.   348 
Data analysis 349 
Double referenced binding data was fitted using GraphPad Prism. The koff was determined 350 
by fitting a mono-exponential decay curve to data from the dissociation phase of each 351 
injection. The koff from four to six RBD injections was averaged to give a value for the koff 352 
(Fig. S3A). The kon was determined by first fitting a mono-exponential association curve to 353 
data from the association phase, yielding the kobs. The kon was be determined by plotting the 354 
.CC-BY-NC 4.0 International licensemade available under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is 
The copyright holder for this preprintthis version posted May 24, 2021. ; https://doi.org/10.1101/2021.05.18.444646doi: bioRxiv preprint 
 14 
kobs vs the concentration of RBD and performing a linear fit of the equation kobs = kon*[RBD] 355 
+ koff to this data (Fig. S3B), using the koff determined as above to constrain the fit. 356 
The KD was either calculated (calculated KD = koff/kon) or measured directly (equilibrium KD) 357 
as follows. Equilibrium binding levels at a given [RBD] were determined from the fit above of 358 
the mono-exponential association phase model to the association phase data.  These 359 
equilibrium binding levels were plotted against [RBD] and a fit of the simple 1:1 Langmuir 360 
binding model to this data was used to determine the equilibrium KD (Fig. 2D). 361 
ΔG for each affinity measurement was calculated the relationship G =R*T*lnKD, where R = 362 
1.987 cal mol-1 K-1, T = 310.18 K, and KD is in units M. ΔΔG values (Table 2 and Fig. 3D) were 363 
calculated for each mutant from the relationship G = GWT − GM. The predicted G for 364 
interactions with multiple mutants were calculated by adding the single mutant G values 365 
(Fig. 3D). The difference between the measured and predicted G (G) for interactions 366 
between the ACE2 and RBD mutants was calculates as G = measured G – predicted 367 
G (Fig. 4B). 368 
All errors represent standard deviations and errors for calculated values were determined 369 
by error propagation. 370 
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Table 1. Affinity and kinetic data for RBD variants and ACE2 variants  
Mean and SD of the koff, kon, calculated KD, and equilibrium KD values for all RBD variants 
binding all ACE2 variants. For most measurements n = 3; the exceptions were RBD WT/ACE2 
WT equilibrium KD measurements (n =24) and other RBD WT measurements (n = 6). UK1, 
UK2, BR, SA refer to the B.1.1.7, VOC-202102-02, P2, and B.1.351 variants, respectively. 
 koff (s
-1) SD kon (µM-1 s-1) SD KD Calc. (nM) SD KD Equi. (nM) SD 
 RBD over WT ACE2          
WT 0.0668 0.00113 0.90 0.05 74.4 4.0 62.6 7.7 
K417N 0.177 0.00416 0.49 0.05 364 29 349 10 
K417T 0.126 0.00510 0.55 0.04 230 23 226 19 
S477N 0.0348 0.00037 0.81 0.03 42.9 2.1 42.6 3.0 
E484K 0.0818 0.00183 1.54 0.03 53.1 1.7 52.6 2.0 
N501Y (UK1) 0.0111 0.00017 1.59 0.04 7.0 0.25 5.5 2.4 
K417N/E484K 0.251 0.00799 1.02 0.07 247 23 251 23 
K417T/E484K 0.168 0.00573 1.10 0.05 153 12 147 8.6 
E484K/N501Y (UK2) 0.0118 0.00037 2.33 0.10 5.1 0.36 3.7 2.7 
K417N/E484K/N501Y (SA) 0.0291 0.00076 1.46 0.06 20.0 0.70 17.4 3.1 
K417T/E484K/N501Y (BR) 0.0211 0.00021 1.56 0.07 13.5 0.45 12.2 3.4 
 RBD over S19P ACE2          
WT 0.0298 0.00039 1.50 0.12 20.0 1.3 30.5 2.2 
K417N 0.0782 0.00284 0.72 0.04 108 2.8 129 8.2 
K417T 0.0521 0.00196 0.69 0.02 75.8 4.7 87.8 7.0 
S477N 0.0257 0.00016 1.05 0.07 24.6 1.7 30.3 2.7 
E484K 0.0325 0.00031 2.02 0.08 16.2 0.55 20.8 1.3 
N501Y (UK1) 0.0051 0.00004 2.31 0.09 2.2 0.09 3.5 0.4 
K417N/E484K 0.0961 0.00198 1.28 0.11 75.6 7.1 91.3 6.5 
K417T/E484K 0.0660 0.00255 1.45 0.03 45.5 2.5 53.8 1.5 
E484K/N501Y (UK2) 0.0051 0.00008 3.10 0.10 1.7 0.05 3.4 0.4 
K417N/E484K/N501Y (SA) 0.0122 0.00009 2.16 0.03 5.7 0.07 10.4 1.2 
K417T/E484K/N501Y (BR) 0.0085 0.00007 2.11 0.05 4.0 0.07 6.1 1.3 
RBD over K26R ACE2          
S477N 0.0240 0.00009 1.07 0.05 22.6 1.1 33.4 1.3 
WT 0.0500 0.00062 1.60 0.16 31.4 2.6 48.8 2.5 
K417N 0.154 0.00789 0.88 0.07 175 8.1 237 15 
K417T 0.101 0.00079 0.81 0.12 127 17.4 154 2.8 
S477N 0.0240 0.00009 1.07 0.05 22.6 1.1 33.4 1.3 
E484K 0.0587 0.00109 2.03 0.03 28.9 1.0 35.9 1.5 
N501Y (UK1) 0.0081 0.00002 2.34 0.09 3.5 0.15 7.5 1.5 
K417N/E484K 0.191 0.00481 1.48 0.15 130 9.4 166 11 
K417T/E484K 0.135 0.00407 1.53 0.02 88.0 3.9 105 0.7 
E484K/N501Y (UK2) 0.0085 0.00018 3.06 0.23 2.8 0.17 6.4 0.3 
K417N/E484K/N501Y (SA) 0.0234 0.00040 2.13 0.05 11.0 0.28 18.7 2.0 
K417T/E484K/N501Y (BR) 0.0164 0.00028 2.21 0.06 7.4 0.33 15.3 0.8 
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Table 2. ΔΔG for RBD variants binding to ACE2 variants 
Mean and SD of ΔΔG (n = 3, kcal/mol) were determined as described in the Materials and 
Methods using the calculated KD values in Table 1.  UK1, UK2, BR, and SA refer to the 
B.1.1.7, VOC-202102-02, P2, and B.1.351 variants, respectively. 
 
 ACE2 WT  ACE2 S19P  ACE2 K26R   
RBD variant ΔΔG SD ΔΔG SD ΔΔG SD 
WT 0.00 0.00 0.79 0.05 0.52 0.06 
K417N -0.96 0.06 -0.23 0.04 -0.52 0.04 
K417T -0.68 0.07 -0.01 0.05 -0.32 0.09 
S477N 0.33 0.04 0.67 0.05 0.72 0.04 
E484K 0.20 0.04 0.92 0.04 0.57 0.04 
N501Y (UK1) 1.43 0.04 2.13 0.04 1.86 0.04 
K417N/E484K -0.72 0.07 -0.01 0.07 -0.34 0.06 
K417T/E484K -0.43 0.06 0.30 0.05 -0.10 0.04 
E484K/N501Y (UK2) 1.62 0.05 2.30 0.04 1.98 0.05 
K417N/E484K/N501Y (SA) 0.79 0.04 1.56 0.03 1.16 0.04 
K417T/E484K/N501Y (BR) 1.03 0.04 1.76 0.03 1.39 0.04 
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Figure 1. Spike RBD and ACE2 variants analysed in this study.  (A)  Phylogenetic tree 
illustrating the clades containing the RBD mutations investigated in this study. Constructed 
using TreeTime (Sagulenko et al., 2018) from the Nextstrain Global (Hadfield et al., 2018) 
sample of SARS-CoV-2 sequences from the GISAID database (Shu and McCauley, 2017) 
(Accessed 15th April 2021, N = 4,017). (B) Alignment illustrating the Spike residues that 
differ between SARS-CoV-2 variants, with the RBD mutants boxed. The variants are labelled 
with their clade designation from Nextstrain (Hadfield et al., 2018) and/or PANGO lineage 
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(Hodcroft, 2021) and Nextstrain. (C) The structure of human ACE2 (green) in complex with 
SARS-CoV-2 Spike RBD (cyan). The area enclosed by the box is shown enlarged on the right, 
with the residues mutated in this study labelled. Drawn using UCSF Chimera (Pettersen et 
al., 2004) using coordinates from PDB 6m0j (Lan et al., 2020). 
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Figure 2. SPR analysis  
(A) Overlay of binding traces showing association and dissociation when WT RBD is injected 
for 30 s at the indicated concentration over immobilized WT ACE2.  The right panel shows 
an expanded view of the dissociation phase. The blue lines show the fits used for 
determining the kon and koff. The kon was determined as described in Fig. S3. The koff (B) and 
kon (C) values measured at different levels of immobilized ACE2 are shown. (D) The 
equilibrium KD was determined by plotting the binding at equilibrium against [RBD] injected. 
Data from experiment shown in A. (E) The equilibrium KD measured at different levels of 
immobilized ACE2 are shown. 
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Figure 3. Effect of RBD variants binding WT ACE2 
Overlay of binding traces showing association and dissociation of N501Y (A) and K417N (B) 
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right panels show an expanded view of the dissociation phase. The blue lines show fits used 
for determining the kon and koff. (C) The fold change relative to WT RBD of the calculated KD, 
kon, and koff for the indicated RBD variants binding to immobilised WT ACE2 (Error bars show 
SD, n = 3). Representative sensorgrams from all mutants shown in Fig. S5, and the mean 
values from multiple repeats are in Table 1. (D) The blue lines show the measured ΔΔG for 
indicated RBD variants. The red lines show the predicted ΔΔG for the RBD variants with 
multiple mutations, which were calculated by adding ΔΔG values for single mutation 
variants (Error bars show SD, n = 3).
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Figure 4. Effect of mutations in ACE2 
(A) The fold change relative to WT ACE2 of the calculated KD, kon, and koff for the interaction 
of WT RBD and the indicated ACE2 variants (Error bars show SD, n = 3). (B-C) Show the 
difference (G) between the measured and predicted G for S19P (B) and K26R (C) 
ACE2 variants binding to the indicated RBD variants, calculated from data in Table 2. The 
predicted G values for each variant RBD/variant ACE2 interaction were calculated from 
the sum of the G for the ACE2 variant binding WT RBD and the G for the RBD variant 
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Figure S1. Emergence of the same RBD mutations in multiple SAR2-CoV-2 clades.  
The figure highlights the SARS-CoV-2 clades containing RBD mutations investigated in this 
study. The phylogenetic trees were constructed as in Fig. 1A from SARS-CoV-2 sequences 
accessed on the 22nd April 2021 (N = 3,914). (A) N501Y has emerged independently of the 
three clades 501Y.V1, 501Y.V2, and 501Y.V3. Mutation to T at this position has also 
occurred frequently. (B) E484K has also been observed independently of its main progenitor 
clades 501Y.V2 and 501Y.V3. E484Q and E484G have also been observed. (C) S477N has 
been observed beyond clades 20F and 20A.EU2. Mutations to I and R have also been 
occasionally observed at this position. (D) Mutations of K417 to N and T have been observed 
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Figure S2. Protein purification  
Size- exclusion chromatography traces of the indicated ACE2 and RBD proteins and SDS-
PAGE of the indicated peak fractions. UK1, UK2, BR, SA refer to the B.1.1.7, VOC-202102-02, 
P2, and B.1.351 variants, respectively.  
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Figure S3. Determining the kon and koff. 
Analysis of data from the fits in Fig. 2A. (A) A plot of koff obtained for each injection versus 
[RBD]. (B) A plot of kobs for each injection versus [RBD]. The line shows a constrained fit of 
the equation kobs = kon*[RBD] + koff, using the koff  obtained in (A). The kon was obtained from 
the slope. 
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Figure S4. Mass transport controls from RBD  
The koff (A) and kon (B), respectively, for E484K/N501Y (UK2) RBD binding WT ACE2 at a 
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Figure S5. Representative SPR data for RBD variants binding to WT ACE2 
Binding traces for the indicated RBD variants injected different concentrations over 
immobilised WT ACE2. The right panels show an expanded view of the dissociation phase. 
The blue lines show fits used for determining the kon and koff. UK1, UK2, BR, SA refer to the 
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Figure S6. Representative SPR data for WT RBD binding  ACE2 variants 
Binding traces for the WT RBD injected at different concentrations over the indicated 
immobilized ACE2 variants. The right panels show an expanded view of the dissociation 
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